Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

Completed

Conditions studied: Eosinophilic Asthma

In brief

The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).

Key facts

Study ID

NCT05002621

Run by

Mayo Clinic

People needed

20

Starts

2021-02-16

Expected to finish

2025-12-11

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old.
• Diagnosis of SEA by a health care provider
• History of an absolute eosinophil count ≥ 300/mm\^3
• Prescription for mepolizumab provided during course of routine clinical care but mepolizumab not yet started

You may not qualify if…

• Age < 18 years old.
• Pregnancy.
• Currently using or have used within 3 months of the initial baseline visit any biologic or immunomodulatory therapy with the exception of #3.
• Currently using or any prior use of rituximab.
• History of upper/lower respiratory tract infection or asthma exacerbation within the previous four weeks of the first baseline visit.
• Any prior history of malignancy, autoimmune disease, or immune deficiency.
• Any other significant medical issue as determined by the principal investigator.

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.